SCHEMBL3391489

SCHEMBL3391489

OC(Nc1ccccn1)c1c(-c2ccc(Cl)cc2Cl)nc2ccccn12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.50
MDM2 Q00987 2/20 0.40
NR1I3 Q14994 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HPGD P15428 3/20 0.37
TP53 P04637 3/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 2/20 0.37
POLB P06746 2/20 0.37
GLA P06280 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PRKD3 O94806 1/20 0.36
PRKCG P05129 1/20 0.36
PRKCB P05771 1/20 0.36
IL1R1 P14778 1/20 0.36
PRKCA P17252 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14632155 0.81 EGLN2 (0.39) DPP4MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL3395698 0.78 PHGDH (0.38) DPP4MDM2KMT2AHPGDALDH1A1
SCHEMBL3395179 0.77 TRPA1 (0.38) DPP4MDM2HPGDTP53GAA
SCHEMBL14632152 0.77 ALDH1A1 (0.46) MEN1KMT2AHPGDTP53ALDH1A1
SCHEMBL15879864 0.76 GAA (0.43) DPP4NR1I3MEN1KMT2ATP53
SCHEMBL3360406 0.74 MEN1 (0.41) DPP4MEN1KMT2AHPGDTP53
SCHEMBL3396264 0.74 CRHR1 (0.38) DPP4TP53ALDH1A1GAAPOLB
SCHEMBL15879650 0.71 SMN1; SMN2 (0.43) MDM2MEN1KMT2AHPGDTP53
SCHEMBL22627536 0.70 DPP4 (0.66) DPP4NR1I3MEN1KMT2AHPGD
SCHEMBL22615070 0.70 DPP4 (0.66) DPP4NR1I3MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS BIOVITRUM AB (PUBL) (SE) 2015-08-27 US disclosed
US-20140206662-A1 Imidazopyridine Compounds PROXIMAGEN LTD. (GB) 2014-07-24 US disclosed
EP-2376490-B1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD (GB) 2013-01-23 EP disclosed
WO-2010064020-A1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD. (GB) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS SSB, MIF, IDO1 DPP4 307/4885MDM2 3074/4885NR1I3 1272/4885
US-20140206662-A1 Imidazopyridine Compounds SSB, NFKBIA, TPMT DPP4 125/4885MDM2 2800/4885NR1I3 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.